Robert B Hawkins1, Jeffrey M Wilson2, J Hunter Mehaffey3, Thomas A E Platts-Mills2, Gorav Ailawadi3. 1. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia. Electronic address: rbh6x@virginia.edu. 2. Division of Allergy and Clinical Immunology, University of Virginia, Charlottesville, Virginia. 3. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia.
Abstract
BACKGROUND: Alpha-gal syndrome is a tick-acquired disease caused by immunoglobulin E (IgE) to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), causing allergic reactions to meat and products sourced from nonprimate mammals. As heparin is porcine-derived, we hypothesized that patients with alpha-gal syndrome who received high-dose heparin for cardiac surgery would have increased risk of anaphylaxis. METHODS: All cardiac surgery patients at an academic medical center from 2007 to 2019 were cross-referenced with research and clinical databases for the alpha-gal IgE blood test. Clinical data were obtained through the institutional Society of Thoracic Surgeons Adult Cardiac Database and chart review. Patients were stratified by development of an allergic reaction for univariate statistical analysis. RESULTS: Of the 8819 patients, 17 (0.19%) had a positive alpha-gal test before cardiac surgery. Of these 17 patients, 4 (24%) had a severe allergic reaction. The median alpha-gal titer was significantly higher in patients with a reaction (75 [interquartile range, 61-96] IU/mL vs 8 [interquartile range, 3-18] IU/mL; P = .006). There were no differences in median heparin loading dose, total dose, or maximum activated clotting time (all P > .05). In a subgroup of 8 patients with recent alpha-gal IgE level, 4 (50%) developed an allergic reaction. CONCLUSIONS: Although alpha-gal is rare in patients undergoing cardiac surgery, there is up to a 50% risk of serious allergic reaction to heparin for cardiopulmonary bypass. Higher preoperative alpha-gal titers may confer a higher risk of severe allergic reaction. For patients with a clinical suspicion of alpha-gal syndrome, we recommend prescreening with IgE levels and premedicating before receiving high doses of intravenous heparin.
BACKGROUND: Alpha-gal syndrome is a tick-acquired disease caused by immunoglobulin E (IgE) to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), causing allergic reactions to meat and products sourced from nonprimate mammals. As heparin is porcine-derived, we hypothesized that patients with alpha-gal syndrome who received high-dose heparin for cardiac surgery would have increased risk of anaphylaxis. METHODS: All cardiac surgery patients at an academic medical center from 2007 to 2019 were cross-referenced with research and clinical databases for the alpha-gal IgE blood test. Clinical data were obtained through the institutional Society of Thoracic Surgeons Adult Cardiac Database and chart review. Patients were stratified by development of an allergic reaction for univariate statistical analysis. RESULTS: Of the 8819 patients, 17 (0.19%) had a positive alpha-gal test before cardiac surgery. Of these 17 patients, 4 (24%) had a severe allergic reaction. The median alpha-gal titer was significantly higher in patients with a reaction (75 [interquartile range, 61-96] IU/mL vs 8 [interquartile range, 3-18] IU/mL; P = .006). There were no differences in median heparin loading dose, total dose, or maximum activated clotting time (all P > .05). In a subgroup of 8 patients with recent alpha-gal IgE level, 4 (50%) developed an allergic reaction. CONCLUSIONS: Although alpha-gal is rare in patients undergoing cardiac surgery, there is up to a 50% risk of serious allergic reaction to heparin for cardiopulmonary bypass. Higher preoperative alpha-gal titers may confer a higher risk of severe allergic reaction. For patients with a clinical suspicion of alpha-gal syndrome, we recommend prescreening with IgE levels and premedicating before receiving high doses of intravenous heparin.
Authors: Thomas A E Platts-Mills; Scott P Commins; Tilo Biedermann; Marianne van Hage; Michael Levin; Lisa A Beck; Maria Diuk-Wasser; Uta Jappe; Danijela Apostolovic; Michael Minnicozzi; Marshall Plaut; Jeffrey M Wilson Journal: J Allergy Clin Immunol Date: 2020-02-10 Impact factor: 10.793
Authors: Christine H Chung; Beloo Mirakhur; Emily Chan; Quynh-Thu Le; Jordan Berlin; Michael Morse; Barbara A Murphy; Shama M Satinover; Jacob Hosen; David Mauro; Robbert J Slebos; Qinwei Zhou; Diane Gold; Tina Hatley; Daniel J Hicklin; Thomas A E Platts-Mills Journal: N Engl J Med Date: 2008-03-13 Impact factor: 91.245
Authors: Susan M Mozzicato; Anubha Tripathi; Jonathon B Posthumus; Thomas A E Platts-Mills; Scott P Commins Journal: J Allergy Clin Immunol Pract Date: 2014-07-25
Authors: Margaret Shin Kim; Matthew D Straesser; Behnam Keshavarz; Lisa Workman; Emily C McGowan; Thomas A E Platts-Mills; Jeffrey M Wilson Journal: J Allergy Clin Immunol Pract Date: 2019-09-11
Authors: Alejandro Cabezas-Cruz; Adnan Hodžić; Patricia Román-Carrasco; Lourdes Mateos-Hernández; Georg Gerhard Duscher; Deepak Kumar Sinha; Wolfgang Hemmer; Ines Swoboda; Agustín Estrada-Peña; José de la Fuente Journal: Front Immunol Date: 2019-05-31 Impact factor: 7.561